Journalists Follow Up on Unused Vaccines and For-Profit Medical Schools
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
FDA
261 - 280 of 471 Results
-
-
KHN’s ‘What the Health?’: The ACA Lives
In a surprisingly strong 7-2 decision, the Supreme Court turned back the latest constitutional challenge to the Affordable Care Act, likely heralding the end of GOP efforts to strike the law in its entirety through court action. Meanwhile, Democratic lawmakers are looking for ways to expand health benefits. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Andy Slavitt, who recently stepped down from the Biden administration’s covid response team, about his new book on the pandemic.
-
Not All Experts Are Ready to Vaccinate Kids Against Covid
Rare reports of minor heart damage have convinced some scientists that further study is needed before racing to extend covid shots to more children.
By Arthur Allen -
Journalists Discuss New Alzheimer’s Drug, Women’s Alcohol Use, the Hip-Hop and Opioids Link
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
-
KHN’s ‘What the Health?’: Our 200th Episode!
The federal approval of a controversial drug to treat Alzheimer’s disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN’s Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast’s 200th episode, the panelists discuss what has surprised them most and least over the past four years.
-
FDA Weighs Approval of a Lucrative Alzheimer’s Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
By Harris Meyer -
KHN’s ‘What the Health?’: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
-
KHN’s ‘What the Health?’: Sharing Vaccines With the World
The Biden administration is bucking the drug industry and backing a waiver of covid-19 vaccine patent protections to help the rest of the world vaccinate its populations. Here at home, the Food and Drug Administration wants to ban menthol flavorings for cigarettes, setting off a fight with the tobacco industry. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Kimberly Leonard of Business Insider join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Detecting Rare Blood Clots Was a Win, But US Vaccine Safety System Still Has Gaps
With some 100 million Americans fully vaccinated, the U.S. is relying on a patchwork network of vaccine monitoring systems that lack the breadth and depth of large, population-based programs, experts said.
-
KHN’s ‘What the Health?’: Pause and Effect on Covid Vaccines
Podcast panelists discuss a range of health policy developments, from the latest in the covid vaccination effort to the HHS budget, among other things.
-
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA’s stamp of approval on old drugs, led to higher prices. It’s scrapped. So now what?
By Harris Meyer -
A Year Into Pandemic, Federal Officials Move to Better Protect Front-Line Workers
Changes would allow N95 sales for industries other than health care and signal an end to the hospital practice of reusing the masks considered essential for worker safety.
-
Analysis: How the US Invested in the War on Terrorism at the Cost of Public Health
After 9/11, as our defenses against international and bioterrorism hardened, our defenses against infectious diseases shrank. By the time a deadly virus arrived on our shores last year, nearly two-thirds of Americans were living in counties that spend more than twice as much on policing as they spend on public health.
-
Scientists Seek Covid Treatment Answers in Cheap, Older Drugs
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
-
KHN’s ‘What the Health?’: Getting Down to Work at HHS
After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.
-
Birx Joins Air-Cleaning Industry Amid Land Grab for Billions in Federal Covid Relief
Air-cleaning companies with limited oversight are targeting a growing market of schools desperate for covid-19 protection. Donald Trump’s former covid adviser lands with one that built its business, in part, on ozone-emitting technology.
By Christina Jewett and Lauren Weber -
The Hype Has Faded, but Don’t Count Out Convalescent Plasma in Covid Battle
The once-promising therapy that infuses blood plasma from recovered covid-19 patients into newly infected people, theoretically to boost immunity, has suffered setbacks. But some proponents say it’s too early to abandon the treatment.
-
To Extract More Doses per Vial, Vaccinators Put Squeeze on FDA to Relax Vaccine Handling Advice
Although vaccine supply is ramping up, the supply gap puts pressure on vaccinating teams to extract every drop they can. Some are asking the FDA to waive guidance against extracting vaccine from two vials with the same needle. It’s worth a shot.
By Arthur Allen -
Pfizer’s Newest Vaccine Plant Has Persistent Mold Issues, History of Recalls
After nearly a decade’s worth of federal inspections, reprimands and corrective action plans, has Pfizer fixed the facility that will be filling vials of its covid vaccine?
-
Ouch! Needle-Phobic People Scarred by So Many Images of Covid Shots
The pictures are on the nightly news, on billboards, bus stop posters and all over social media. How can people who fear needles manage to get their covid shots?